ISSN: 1165-158X

細胞および分子生物学

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Lipid-Based Therapeutic Strategies for Sarcopenic and Dystrophic Muscular Impairments

Gregory C. Henderson

The ability to perform muscular work is critical for maintaining health and performing activities of daily living. However, numerous individuals are afflicted by pathologies that limit strength or endurance, such as sarcopenia of aging or muscular dystrophy. These pathologies can be associated with increased mortality risk and shortened lifespan; therefore, improved therapies are needed for treating disorders of skeletal muscle and those that generally affect physical function. Esterified and non-esterified lipids within muscle and other cell types exert metabolic and structural effects that alter biochemistry and physiological functions. Importantly, the composition of dietary fat impacts the variety of fatty acids [FAs] in tissue lipids. In this report, recent discoveries on the effects of dietary FA composition are discussed for pathologies related to skeletal muscle and physical work capacity, with the focus placed upon muscular dystrophy and sarcopenia of aging. Potential effects of n-9 monounsaturated FAs [MUFAs], n-3 polyunsaturated FAs [PUFAs], n-6 PUFAs, and trans-FAs [TFAs] are discussed. Potential benefits of MUFA and discordant findings for n-3 PUFA in muscular dystrophy are discussed, as well as the detriments of TFA and benefits of n-3 PUFA in sarcopenia. Other observations and inferences are considered, and areas for future work are identified.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。